Publications by authors named "Lahtinen Perttu"
Imbalanced microbiota may contribute to the pathophysiology of irritable bowel syndrome (IBS), thus fecal microbiota transplantation (FMT) has been suggested as a potential treatment. Previous studies on the relationship between clinical improvement and microbiota after FMT have been inconclusive. In this study, we used 16S rRNA gene amplicon and shotgun metagenomics data from a randomized, placebo controlled FMT trial on 49 IBS patients to analyze changes after FMT in microbiota composition and its functional potential, and to identify connections between microbiota and patients' clinical outcome.
View Article and Find Full Text PDFArticle Synopsis
- * The trial involved 48 patients with PD, examining the effects and safety of a single-dose FMT or a placebo, with key assessments done at 6 months.
- * Results displayed no significant improvement in PD symptoms between FMT and placebo groups, with more gastrointestinal adverse events reported in the FMT group, while some secondary measures showed better outcomes in the placebo group.
Background: Chronic fatigue syndrome (CFS) is a disabling illness of unknown aetiology. Disruption of gut microbiota may play a role in several neurological disorders. In this study, the effect of faecal microbiota transplantation (FMT) on fatigue severity and health-related quality of life (HRQOL) in patients with CFS was evaluated.
View Article and Find Full Text PDFBackground: Irritable bowel syndrome (IBS) is the most prevalent gastrointestinal disorder in developed countries and reduces patients' quality of life, hinders their ability to work, and increases health care costs. A growing number of trials have demonstrated an aberrant gut microbiota composition in IBS, also known as 'gut dysbiosis'. Fecal microbiota transplantation (FMT) has been suggested as a treatment for IBS.
View Article and Find Full Text PDFBackground: Fecal microbial transplantation (FMT) is a promising new method for treating active ulcerative colitis (UC), but knowledge regarding FMT for quiescent UC is scarce.
Aim: To investigate FMT for the maintenance of remission in UC patients.
Methods: Forty-eight UC patients were randomized to receive a single-dose FMT or autologous transplant colonoscopy.
Importance: Severe obesity is a major health concern. However, a few patients remain resistant to bariatric surgery and other treatments. Animal studies suggest that weight may be altered by fecal microbiota transplantation (FMT) from a lean donor.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the reasons for treatment interruptions in patients using TNF-inhibitors (infliximab and adalimumab) and how these interruptions impact immunisation and treatment switching.
- Based on a survey of 370 patients from various hospitals in Finland, it was found that treatment interruptions were significantly linked to immunisation and more common among those treated for rheumatic diseases.
- The most frequent interruption cause was infections, and such interruptions can lead to increased immunisation risk and a greater need for switching medications, highlighting the need for careful clinical decision-making.
Background: Irritable bowel syndrome (IBS) has been associated with microbial dysbiosis.
Aim: To investigate the efficacy of faecal microbiota transplantation (FMT) in the treatment of IBS.
Methods: Forty-nine IBS patients were randomised to receive autologous or allogenic FMT via colonoscopy.
Fecal microbiota transplantation (FMT) is effective in recurrent infection (rCDI). Knowledge of the safety and efficacy of FMT treatment in immune deficient patients is scarce. FMT has been suggested as a potential method for an increasing number of new indications besides rCDI.
View Article and Find Full Text PDF